| Pharmaceutical Bulk Drugs and Intermediates | Production and sales of active pharmaceutical ingredients and key starting materials. | Growing expertise in pharma bulk drugs, compliance with industry standards, and strategic pivot in 2024. | B2B focus serving pharmaceutical manufacturers globally. | Active Pharma Ingredients contributing to higher margins. | 64 | 100 | Revenue through product sales to pharmaceutical companies on contract basis. | Direct sales with contractual agreements; recurring revenue streams. | Rising global demand for essential pharma ingredients, company’s shift to pharma manufacturing. | |
